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• Intrecoronery Irbeaartan Inomeaes Myocardia l  
Perfuelon end Mlcroveacular Blood Volume In e 
Pig Model of Acute le:hemia 
A, $chmermund, L. Lerman, J, Rumbarger, P, Lund, P, Sheedy, E, Ritman, 
M~yo Clinic, Ro~he~fer, MN, USA 
Anglotsnlln II (Ang II) I,= a potent direct vasoconstrictor, In acute Isehemla, 
blockade of Ang II may have beneficial elfects on the coronas/mlcro~lmula. 
lion, We evotusted Ifbosartan Orb), o novel specific Ang II receptor antagonist, 
In a pig model at baseline and during aauts lechemla, 
Elo,~on.baam CT (EBOT) was padormed In g pigs for quantification of 
myo~llSl I~lfuslon (MP) and Intmmyooardlat vu¢~ular blood volume (BV) 
at the mid.ventricle, lodlnated contrast was Injected Into the LAD to define the 
myo¢ledium "at risk' and into the right atrium for examination of MP and BV 
It  blleUrie, during Inluslon of 50 .g/kgtmln adenosine (Aden) into the LAD, 
and Iftef Inaction of a bolus at 0,2 mg/kg Irb into the LAD, To induce souls 
Ii0hlfflla (aT-ngment and T.wave changes), 1,~ M l't l=m mloroapheros 
were Iflle0ted Into the LAD, and MP end BV worn again examined at rest, 
during Aden, and after fib, MP and BV were compared between the LAD 
region 'at flsk' (L) end =in Infaro-lalaral genital region (C), and UC wa~ 
oal0ulated (table, values are mean [SOl), 
MP (IV 
RaM Aden hh Rest Aden I~ 
(l~eeli~) Io,o.) la3~} 10,~] IO, tol IOe~l 10.~oi 
RSt~ I~ 0~'  078 'r 0,74 't O03" 074 0 73 
• ~ g ~ 0,t v~, 'allellee Reel', t ~ p ~ 0, t v~, 'isoham~a Rest" 
Gofx~/on: Intra¢omnan/Id~esahen preserves regional BV during acute 
In,hernia and Increases regional MP similar to adenosine, Irbasahen is a 
comnaty vuedllalor 8t feet and during acute Ischemla, 
• leopmetano, 8-Epl Pmeteglandln F~(~, In the 
PMhogeneale of  le©haemlo Heart Oleeaee 
B,M, Kromer t, J,.C, Kaskt, A, Murday, B, Madden, J,R, TlppinsL 
De~t  ot B/ocmm~Is~)~ tmper/af CaUses, LeSSon, UK; C.aro~ofogcat 
S¢~nce.~ St. Gemge~ He.a t  Medical School, London, UK 
Bact~gt'oun,/: lsoprostenas have been shown to be a reliable index el oxidant 
strata in viva, We have also shown that one of these compounds, 8-epl 
proetaglandln (PG) F~ has a potent vasoconstflctlve action in bovine and 
pe¢Ine comnsry a~dea, in this study we measured levels el 8.epl PGF~ 
in pallonls with acute and chronic ischeamlc heart disease and assessed the 
motor response of isolated human coronary aderies to the administration of 
Isopmalane. 
Mefl~d~ and Resu~: Levels at 8-apt PGF~, (n systsmlo venous plasma 
were measured by enzyme tmmunnassay, Reactivity ot coronary ahen/rings 
to 8-ep( PGF~, the thromboxane mlmal!c, U46619 and PGFo,, were deter- 
mined In ~ Control levels o! free Isoprostane were 50,57 ± 7,63 pg/mt 
(n = 12), whilst levels In age matched coronas/aden/disease patients were 
greatly elevated with chronic stable, unstable and myocardial Infamtlon pa- 
rients having levels el 181.16 ± 32,85, 280,30 ± 58,06 and 348,77 ± 79,81 
pg,~ml respectively (n = 13), This increase in Isoprostano levels was inde- 
pendent of risk factom such as cigarette smoking and diabetes mollitus, 
8.apt PGF~,, also constricted human coronary ahery rings in a concentra- 
tion.dependant fashion with an ECso of 395,4 -~ 62,9 nmol/L (n = g). The 
thromboxsno ,% mimetic, U46619 and PGF~ also corn,lacteal human coro- 
nary vessels as did the prostanold PGF~ with EC50 ~.aluea of 26.2 ± 8.1 
nmol/L (n = 9) and 9g7,4 ± 150.1 nmol/1. (n = 9) respoctlvety, 
CenSus/one: Venous tevets of 8-epl PGF~, are increased in ischeamic 
heart disease, presumably as a consequence of synthesis in the coronary 
vasculature where they have a potent vasoconstrictor effect. Isoprostanes 
produced locally In the coronary adedes during conditions of oxldent stress 
may play • rote in the pathophystok~jy of myocardial ischeemle. 
• Lovastst ln Inhibits Plasminogen Act ivator 
Inhibitor Type-1 Production by Adlpocytes 
T. Sakamoto, J. Woodcock-~itchell, K. Marutsuka, B.E. Sober, S. FujiL 
Univemi~ of Vermont College of Medicine, B,:rlington, ~ USA 
Ba¢,~,~,-o,Jnct: Obesity predisposes to attenuated tibrinolysls attflbutable to 
increased concentration in blood of plasminogen activator inhibitor typed 
(PAl-1), We have previously reported that umor necrosis factor-alpha (TNF.~), 
known to be increased In association with human obesity and insulin resis- 
tanca, stimulates PAl-1 production mediated by reactiva oxygen center,,o 
radicals. Lovastatin, a hydroxymethyl glutaryl coenzyme A (HMG-CoA) re- 
ductese inhibiter can bind free radicals and transitional metal ions and thus 
may act as an antloxldent, 
Morh~s: To determine whether antloxtdent pmpaNlas of lovastatin reduce 
edipocyte generation of PAl.t, 3T3.L1 mouse praadlpo,=ytea were differan- 
tlatsd Into adlpoaytea nd to.incubated with Iovastatln (6 #,g/ml) for 5 days, 
The conditioned media wen) assayed for PN.I by Western blotting and for 
plasmlnogen aetlvatom (PA) a~lvlty by zymography. 
Reau~: TNF,.~ (10 ng/ml) significantly Increased edipoeyto PAl-1 produc- 
tion (0,2 ~: 2.4 fold) (mean :1: SE) (n • 6) compared with that In c~'ltm~a (p 
< 0,01) and deGmasad PA activity In the media, "Do effect of TNF,~ was 
completely Inhibited by the concomitant press.ca at hydroxyl redio~ i~av- 
anger, tetramothylthloun~ (R0 raM) (1,t * 0,t fold) or Iowatatin (1,2 * 0.S 
fold), Urea (R0 raM), used as control, had no effects, Fun'harmers, Iovaatatin 
radu0ed basal (wlthntlt TNF.~) PAI-f production by adipoo/te=. 
Concluak)na: These moults suggest that IovaMatm inhibits PAid produc- 
tion by adlpoGytea and may nolmaltze the othefwiSQ diminished fitmnotyt~ 
activity In obese subjects, Beneficial effec~ ot Iovastatin in ilchami~ bean 
disease may ba attributable tn l~rt to its antloxtdant probates and normal. 
tzatlon el tlorinolylle system dysfunction, 
~ Effect n! In Nond!et~t lo  Patkmtt With Tmgl!tmmne 
Coronary  Artery O!euee  
S, Sunayama, Y. Walenaba, H, Ohmura, M, Sawano, T.C, Ohmura, S. Itch, 
H, Mokuno, H, Daide, H, YamaguchL Doper/mere of Cam~ Juntendo 
Un/vem~ ~ Japan 
R,w~gfound: Insulin resistal~e is a common finding tn patients w4th 
ahen/dtaeema (CAD). CompeneatoW hype(tnsulinemla nd associated tq~d 
diaof~efe have I~n 8ug~stsd to play an impatient rots in the deva lo~t  
el CAD. TmOiltl~ena, a novel insulin sensitizing and antK~idant agent, may 
improve these metabalic dlsoldem. 
Methods: Wa performed a standard 75 g oral glucose t~erance test 
betem and after the administration el troglitazone 400 mg dally for 4 ~.¢.k3 
in 6 nond|abet~ CAD pat',eats, all ot whom had hypennsulieam=¢ 
to oral glucose load. Lipepmtein lipase (LPL) levels in post hopa.n plasma 
and thiobalbituno acid reactive substances (TSARS) as an index of q~,d 
peroxtdalton were also determined. 
Reauff~: Alter the treatment, the plasma insulin m ~  significantly 
decreased with the mean incremental area under the curve (AUC) hem 162 
± 46 to 93 :l: 28 I~U.WmL (p < 0.01). The AUC o! the plasma glucose was 
unchanged, (267 ± 55 to 249 ± 82 mg.WdL p : NS). Although tlro~itazone 
improved neither elevated plasma tdgtycedde (228 ± 114 tO 172 ± 53 mg~lL 
p = NS) nor decreased high density lipopmtein levels (39 ± 9 tO 42 :t: 9 
p : NS) to a signllcant degree, a rise in LPL levels was observed in all el the 
patients (167 ± 68 to 199 ± 88 ng/mL p < 0.05). Additionally. improvement 
in susceptibility to lipid pemxidation was also observed with mean plasma 
TBARS level from 3.67 ± 1.07 to 2.62 + 0.84 nmol/mL (MDA Eq, p < 0.01). 
ConclusK)n: Treglitazone improved the atherogenic lipKI protiles as well 
as the insulin response in patients with CAD and insulin resistance. These 
data suggest treglitazona may confer clinical benefits in the selected patients. 
~':1"9"7--~-~4-'1 Response of  Ant ibodies  Oxidized LDL In to  
HypemboleMerotemlc Patients Treated With 
HMG.CoA Reductaee Inhib l tom 
M,N. Bui, G. Moutealsos, M. Cauffield, C. BuS. B. Echard, CE. Rackley. 
Georgetown UnNe~'s~. Washington. DC. USA 
HMQ-CoA reductase inhibitore slowed anatomic progression at atheroscle- 
rouse and decreased cardiovascular events. Twenty six patients with hy- 
porcholesterolsmie were treated for one year, 18 with HMG-CoA reductase 
inhtbitOrS (11 men, mean age = 55 ± 6). 8 with diet (4 men, mean age = 66 ± 
9). Lipid concentrations and Ab t(ters to OxLDL were measured at baseline, 
6 months, and 12 months. In patients treated with HMG-CoA reductase in- 
hibitors, LDL cholesterol decreased by 26 + 8% and 30 • 12% at 6 months 
and 12 months, respectively. The Ab to OxLDL rose from baseline value 
(optical density) of 0,101 ± 0.07 to 0.160 ± 0.07 at 6 months (p = 0.008) and 
remained elevated at 0.136 ± 0.06 at 12 months (p = 0.048). Patients treated 
with diet showed similar degree of LDL cholesterol reduction to the other 
group at 6 months (p = 0,99), and at 12 months (p = 0.74). Autoantibodies to 
OxLDL, 0,145 ± 0,123 at basline, remained unchanged at 0.091 ± 0.136 (p 
= 0,454) at 6 months and 0.102 ± 0.079 (p = 0.428) at 12 months. Changes 
in LDL cholesterol levels from baseline did not correlate with changes in Ab 
levels in either groups. 
Conclusions: Hyperchole~terolemic patients treated with HMG-CoA re- 
ductase inhibitors revealed a rise in tlters of Ab to OxLDL after six months, 
and liters remained elevated at 12 months. Mechanisms may involve mobi- 
lization of OxLDL within the plaque, as well as removal of the OxLDL from 
the plaque. The dse in Ab to OxLDL may stabilize plaque as well as protect 
uninvolved segments of the blood vessels, hence, a reduction in cardiovas- 
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culer evl~l~l This iS cormstent with recent study showing protechve effect of 
immunizing LDL r~mptor-deflcmnt rab~ts with OxLDL, 
~ ClmulMory Effo¢l~ of Nl¢orandll After Flint [lose 
and Alter Repeated Dosing 
U, Thadam. ~ ot O~. .a .  O~ahorna C~, O~a,  USA 
N~'ofalld;! (NIC) Is a ru¢otmama:le d(~ivatw~ (n,[~_ H y ~ ]  racottnam~:~te 
~rate), which m'~pmv~ (~mae/~ gow and m an ami~chem¢ agent, 
but tm~ke mwahm ~ ¢*mn',~d not to be mmocmte¢l wrm de',~lormment of
!n a ~ l~nd ram~mlzed CroSsover Mud~ m 14 paf~mts with ~ 
emgm~ pectoe~, eltects o! t 0 mg NIC o~ placelpo (PL) on ,~%'tJfl bk~x) pm~swe 
(~P) ~d bean ra~ m ~alualed Mter ~ f l~  d0se ar~ a:'.-xer 2 weeks 
dose. Comlmmd Io ~ vames changu ~n sysfo~ (S) ard ~ c  (d) 
BP and ~ mm (HR) m the ~ p0s~0n aftsr !1~ first (~R~ ~ after 
~ : .~ ,a  ol I~1 emramt were: 
! l-imm~ 4 Hours aHou~ 
N~C e~. mC ~ ~C PL 
(S|BPIstDO~e -2~" -3 -tg' 0 t6" -4 
D~tt4 -it -4 5 ~t2 -3 
(D)BPt=Do~ .-t3" -~ -t3" -i -~2 -5 
Day t4 -7 -3 -7 -4 -4 -2 
(HR) tslDo~e 12 1 3 4 2 3 
O~et4 3 -2 -5 4 4 S 
Dala show h'lat r.~t dose ol 10 mg NIC emptied s~mficant clmtdalory 
eltects Ira- at leas1 up to 8 houm b~ me peak ~,',~ct and du~a~ o~ effec~ 
m~re ~ ammuam~ am~ re~ea~m ~.  Thos. ~ ~o pmra~ 
v~ew, ll~s sludy shows that c ~  torrance dm¢=k~ps fogom~g ~ 
eq~sme to ntcorandd. 
What Ro~e Ooes Uann.ol may In PnmmU.g 
Commst ~ ?  a ~ Ana~ts 
KJ. Tobm. P.A. McCultough. J.P. Speck. D.C. Westveer, OA. Guido-Nten. 
O.S. I"lmleNm~, S.B. ~ . -Ochod0,  W.W_ O'Nei,, M. Stmmns. 
Diwskm of Cardiovascular Medich'm, Her~. Ford a~d Vascuiar lnst;r~ 
Hemy Fo.rl Heat~ b~.  One Ford mac~ S~te 3C, Detro~ Mt 48202. 
USA 
Rece~ ~ have shown ltmt ~ use of mannttot may mcm~se renal o~t- 
ge~ demands, and deslm~, causing an osmot¢ diurems, may be ,n]u.ou~ to 
renal ~ after vascular contrast exposure. It's use. ~-=mfom, as a l~ro- 
phytact¢ agent to prevent contrast ~ t h y  after coronary 
remains controvers,~. As part of the PRINCE (Prmmr~r~n of Rad~K:ormast 
Induced Nephropathy Evaluat~0n) Tnal. palmnts ~ were ~ to a 
forced dmmsLs protocol (fumsemide I mg/kg WP and dopamme 3.g/kg/mm 
IV) and had a mean pulmooary capdla~ wedge pmssu~ <20 mmHg at the 
sta~ ot the procedure, received intravenous marmitol 12.5 oj1~g over 2 I'mum 
This administmtmn occurred clunng ~e conlrasl exposure and was foffo~ed 
by Ii~lrahon with 0.5 NS IV at a rato to match the urine oulput. As dictated by 
the protocol, those who were selected for mam,lol had a k~er mean PCWP. 
14.4 vs. 26.1 mmHg. p = 0.0009. The mean baseline serum c1"eatimne (Cr) 
was 2.2 ± 0.38 vs. 2.59 ± 0.94 in the mannttokexpased (groc~ 1, n = 22) vs. 
the mannitol-unexposed (group 2. n = 76), p = 0.05. Groups 1 and 2 were 
othe~rise sin~lar with respect to confotmdem including diabetic status and 
contrast volume received. The mean induced urine flow rates were 167.62 
± 58.00 vs. 133.20 ± 55.63 mYmin/over 24 hours, p = 0.02, in groups 1 and 
2 r e ~ .  The resultant mean Cr at 48 houm after contrast exposure 
was 2.72 ~ 1.19 vs. 3.11 ± 1.21 mg/dl, p = 0.22, and the mean ~ 1  
increase in Cr was 0.61 ± 0.98 vs. 0.58 ± 0.72 mg/dl, p = 0.88, respectrvely. 
Conclusions: Despite its use in patients with mote favorable renal funchon 
and hemodyrmmic profiles, the controlled, pmspectnte IV administration of 
mannitol was not effectwe in preventing renal injury despite augmentato'~ of 
a forced diuresis with other agents. 
~ A Randomized "t~ial of  Prevention Measures in 
Patients at High Risk for Contrast Nephropathy: 
Initial Results of  the PRINCE Study 
M. Stevens, P.A. McCuilough, K.J. Tobin, J.P. Speck, D.C. Westveer, 
O.A, Guido-Allen, D.S. Hartenburg, S.B. Puchrowicz-Ochocki, W.W. O°Neig. 
Division of Cardiovascular Medicine, Henry Ford and Vascular Institute, 
Henry Ford Heaffh System, One Ford Place, Suite 3C, Detroit, M1482~.,2o • 
USA 
Recent studies from series of PTCA and CABG patients indicate that baseline 
renal o~furctmn m an indelmndem IXe<~cfor f monal~ after ~ ~,-~,. 
cl.res. We have pmv~usly tmown a gra0~l mlatmmm~ w~ me ¢ ~  ol 
renal failure and ~ Im:~l~y of m-homital death m Im,mn~ un(~ 
Io0p ~urel¢~, mannitol) have 8ho.~ no clear ~ ~ I 
of patmm= m r~m, We Nt  out t ~ ttm the ~ .,~t a fo¢=¢1 ¢~nm 
a~er me con.a~ e~Do~um w~h a ~ of me~ ~mu~ m~u~ m 
a mduce~ ~me c~ re.al U~r~ ,n ~ ~mm~ w e ~ m  
0,9 mg/~, The ~m~Im were ~,~lar with rL~xcl to age, W~l~ ~:~¢ 
edent 0t i~ml  vMctll~r ¢lileMe, The f0R~Kl ~tmm~ fwct~e¢l m 
um~ flow rallm, 1~3 ~ ~4 vs. I~3 ~ SS ml/hr, O~e 1he ~4 h~um gtef ¢o11~11t 
exposure (p ~ 0.001), Thrum ~ m ~ tugil~lt ~ ~ ~ fl(mH1d 
the s r~J  memase m ~ Cr, 03 ~ 0.6 v~ O.g ± 0,9 mQ~l m me lowest 
,n ~he ~ace~o a~m re~ ~ w,~ a. ~ ~ .avr.g meam.~d 
d ~ pem~ begmm~ at the mn ol am~gmp~ o~ ~me~m 
to ~ a unne go~ ra~e of ~, 145 m~hr m me 24 houm aftra me pm¢e~m, 
Heart Failure: Beta Antagonists 
Wednesday, Apnl 1, 1998, Noon-2:00 p.m. 
Georgia Wodd Congress Center. West Exhibit Hall Level 
Presentation Hour. 1:00 p.m.-2:00 p.m. 
Canmdl~l  Inhibits EndoUtelln-1 B lo lyn lheMI  In 
Cu~med Human Coronary Ar~ry ~ l  
EH G~i~,~, G. ~ , / L M .  Romanic, R.R. Ruff~o, Jr.. ~ 
ot Ca,~,~asc~ar P~n~aco~j~, ~ B=~c,~,~ Ptwmz¢e=,¢a~, 
K~ng o~ P~. ,~.  R~ 19406. USA 
It has been m¢~,~-y ~ed thai CHF pa~e~s mm~d ~ car~lo l  have 
s~j~mr~y _r,~,___,c.~__ cmmmm~g ,~-~I  (ET-~) ~ as compared to 
~mm~ed mments. The m~c~ms m p~sma ET-I k.,e*s cormmnmU 
~th a ~ ~ ~ in va~m~ immmemm uud to mea- 
sure the ~ ~ ~ of head P=tiiurB. ~ ,  the f1~ch~-~i~.T~ 
for the ciecmase rn ET-1 was not known Tt-¢=~fore, rne f,,-=s~ s~,~'y was 
des-~g~..d to ~ me d~mct effects of cen~d~m* on ET-I 
5~S in ct.d~fed ~ corollary ~f1~ erl~0~hellal ~ (HCAECs). HCAECa 
were tmaP~J w~h canmd~lol 15 rmn Ire'lot o file ado~itlon of see.~n and ET-1 
levels were measured in the ~.~.~;;~..,,~,.~ mlmlnJ, m 24 hr later. ~ Ira> 
a ~ !  ml~mn of r, emm-med~ 
of ET-I bmsyne~ms ,~th an tC~ = i uM. Pm1~roE'r-1 mRNA e~easmn 
was also mhil~ted by carvedlol maln~nL Oe~r p -adnmo,~v~v a~ago~sls 
such as proprar~ol (10 uM) o~ ce~pm~ol (10 uM) did no~ effect ET.1 
thess. Fu'~e~mmo~, me amh~,~ant IXObUO~ (10 uM) ~ not enect ET-1 
product~n, fo'~muno-hisfochE~cel analys~ of HCAECs silo demonstmtsd 
b~at cenmd~of mh;b;h~3 ET-1 ~ .  These data ~te  thal cenm~Iof 
o~rec~ mhil~s me Im)syne~,s of ET-I in HCAECs, and this effect may 
con1~Imle to its ~,a;.-.;~lat mg and anlqamlifmaftve actions. Fmlhermom. these 
effects may contnbum to the ab~ltty of cantedilof to improve dtnlcal outcome 
in CHF paftents. 
~ Ooes Canmdllol Inhibit Aorlal  Smooth Muscle Cell 
Prol l femtlon? 
P. Mohacsi', K. PI0Ss ~ , HU. Tschanz ~ , S. Gasoflefl I , R. Asm~, 
G. Spon~. ' C ~  U,",tt~t~," ~ Bert,., Gerrp~.t~/; 21.q'Mffu'te of
Biochemistry.. Untversdy of Basel, Germany: ~Boehnnger-Man~ll~m, 
Marmheim. Germany 
Canmdilol [C] is a multiactiog ant]hypertenshte drug recently also apf~oved 
for the treatment of heart failure and combines ~- with a~.bloCking and an- 
tioxidant activities. It was shown that C protects the vasculalum from chronic 
pathological processes such as ischemia, atherosck~osts and remodelling 
that is observed in the cardiovascular system after pressure overload and 
shear stress. To evaluate the antiproliferatwe activity of C on human aofffc 
vascular smooth muscle ceils [SMC], we tested the influence of C and of 
diff ~ ~_nt agents whc'h contnbute to C's activity. SMC were cultured under 
serum free conditions and either treated for 6 hm wffh different cor~-,,;,~- 
tions of C, C's metabofite BM 91.0228 IBM] [without ~.blocldng, but 30.fold 
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